Reproductive · Genitourinary Syndrome of Menopause
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Genitourinary syndrome of menopause (GSM), formerly termed atrophic vaginitis or vulvovaginal atrophy, is caused by estrogen deficiency affecting the vulvovaginal and lower urinary tract tissues, leading to thinning of the vaginal epithelium and loss of rugae.
The most common clinical presentation is dyspareunia, vaginal dryness, and pruritus in a postmenopausal patient; urinary symptoms such as urgency, dysuria, and recurrent UTIs are also part of GSM.
Physical examination reveals a pale, dry, and friable vaginal mucosa with petechiae or fissures.
The vaginal pH in GSM is typically elevated (>5.0) due to the loss of lactobacilli and glycogen.
First-line treatment for symptomatic patients is low-dose vaginal estrogen therapy.
Vaginal estrogen is preferred over systemic menopausal hormone therapy (MHT) to minimize endometrial and breast side effects.
Patients with a history of estrogen-dependent cancer (e.g., breast cancer) should be managed with non-hormonal vaginal moisturizers or lubricants first.
Vignette unlocked
A 62-year-old postmenopausal woman presents to the clinic complaining of 4 months of progressive vaginal dryness and pain with intercourse. She reports no abnormal bleeding or discharge. On physical examination, the vaginal mucosa appears pale and thin with a loss of normal rugae and scattered petechiae. A vaginal swab reveals a pH of 5.5 and the absence of hyphae or clue cells.
What is the most appropriate initial treatment for this patient?
Low-dose vaginal estrogen
The patient's presentation of dyspareunia, elevated vaginal pH, and pale, friable mucosa is classic for genitourinary syndrome of menopause (GSM, formerly termed atrophic vaginitis), which is best treated with local estrogen therapy.
Full handout
High yield triage
Etiology / Epidemiology
Occurs in postmenopausal women due to estrogen deficiency following ovarian failure.
Clinical Manifestations
Presents with dyspareunia, vaginal dryness, and pruritus, often with urinary urgency, dysuria, or recurrent UTIs; exam shows pale, thin, dry mucosa.
Diagnosis
Clinical diagnosis; pH > 5.0 and maturation index showing parabasal cells.
Treatment
Vaginal estrogen is first-line; with a history of estrogen-dependent cancer, use nonhormonal therapy first; low-dose vaginal estrogen may be considered with oncology input if refractory.
Prognosis
Chronic condition requiring long-term maintenance; high risk of recurrent urogenital atrophy.
Full handout
Epidemiology & Etiology
Genitourinary syndrome of menopause (GSM), formerly atrophic vaginitis or vulvovaginal atrophy, affects up to 50% of postmenopausal women. Primary cause is the cessation of ovarian estrogen production, leading to the loss of trophic support for the urogenital epithelium. Smoking is a significant risk factor as it accelerates the decline of estrogen levels.
Pertinent Anatomy
The vaginal epithelium, urethra, and bladder trigone are highly estrogen-sensitive. Loss of estrogen causes the vaginal rugae to flatten and the epithelium to become thin and friable.
Pathophysiology
Estrogen deficiency leads to a decrease in glycogen content within vaginal epithelial cells. This reduces the substrate for Lactobacillus, causing a rise in vaginal pH. The resulting alkaline environment promotes the growth of pathogenic bacteria and increases susceptibility to urinary tract and vaginal infections.
Clinical Manifestations
Patients report vaginal dryness, burning, and dyspareunia, and may report urinary symptoms such as urgency, frequency, dysuria, or recurrent urinary tract infections. Physical exam reveals pale, thin, dry mucosa with loss of rugae and petechiae. Red flags include postmenopausal bleeding, which warrants prompt evaluation to rule out endometrial cancer.
Diagnosis
Diagnosis is primarily clinical, based on bothersome genital, sexual, and/or urinary symptoms with consistent examination findings. Vaginal pH > 5.0 is a key indicator. Microscopic evaluation of a wet mount reveals a maturation index shift toward parabasal cells and a lack of superficial cells.
Treatment
Vaginal estrogen (creams, rings, or tablets) is the first-line treatment for symptomatic relief. Contraindications include undiagnosed vaginal bleeding, known or suspected estrogen-dependent cancer (low-dose vaginal estrogen may be considered in consultation with oncology for survivors with GSM refractory to nonhormonal therapy), and history of DVT/PE. Non-hormonal vaginal lubricants are used for mild cases or as adjuncts.
Prognosis
Symptoms are chronic and typically recur upon cessation of therapy. Long-term maintenance is often required to prevent recurrent urogenital atrophy and associated urinary tract infections.
Differential Diagnosis
Bacterial Vaginosis: presence of clue cells and fishy odor
Candidiasis: thick, white, curd-like discharge
Trichomoniasis: strawberry cervix and motile trichomonads
Lichen Sclerosus: white, parchment-like skin changes
Endometrial Cancer: postmenopausal bleeding is the primary concern